{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:39:58Z","timestamp":1771061998698,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jaip.2018.01.037","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T21:38:42Z","timestamp":1518212322000},"page":"2081-2086.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet"],"prefix":"10.1016","volume":"6","author":[{"given":"Hendrik","family":"Nolte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon L.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodil","family":"Svanholm Fogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernt","family":"Hus\u00f8y","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.01.037_bib1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00002018-200528110-00006","article-title":"Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods","volume":"28","author":"Wernicke","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2018.01.037_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-144-4-200602210-00007","article-title":"Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial","volume":"144","author":"Bent","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2018.01.037_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/014107689108400612","article-title":"Spontaneous adverse drug reaction reporting vs event monitoring: a comparison","volume":"84","author":"Fletcher","year":"1991","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.jaip.2018.01.037_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaci.2013.03.039","article-title":"Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language","volume":"132","author":"Passalacqua","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.01.037_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/00325481.2017.1308208","article-title":"Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma","volume":"129","author":"Brunton","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jaip.2018.01.037_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1939-4551-7-6","article-title":"Sublingual immunotherapy: World Allergy Organization position paper 2013 update","volume":"7","author":"Canonica","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2018.01.037_bib7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.01.037_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2014.03.019","article-title":"Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Mosbech","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.01.037_bib9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2016.06.044","article-title":"Efficacy of house dust mite SLIT-tablet in North American adolescents and adults in a randomized, placebo-controlled trial","volume":"138","author":"Nolte","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.01.037_bib10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jaci.2014.12.1911","article-title":"Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber","volume":"135","author":"Nolte","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.01.037_bib11","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2018.01.037_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000444016","article-title":"Fractionation of source materials leads to high reproducibility of SQ HDM SLIT-tablets","volume":"169","author":"Henmar","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.01.037_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40271-017-0217-0","article-title":"Development of a report card for identifying local sublingual immunotherapy events in clinical trials","volume":"10","author":"Norquist","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.jaip.2018.01.037_bib14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/00325481.2017.1302306","article-title":"A\u00a0practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice","volume":"129","author":"Bernstein","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jaip.2018.01.037_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anai.2015.10.024","article-title":"Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites","volume":"116","author":"Maloney","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.01.037_bib17","author":"European Medicines Agency"},{"key":"10.1016\/j.jaip.2018.01.037_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2018.01.037_bib19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/PSY.0b013e3182294a50","article-title":"The nocebo effect and its relevance for clinical practice","volume":"73","author":"Colloca","year":"2011","journal-title":"Psychosom Med"},{"key":"10.1016\/j.jaip.2018.01.037_bib20","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.ehj.2003.08.016","article-title":"Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo","volume":"24","author":"Silvestri","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaip.2018.01.037_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.01.037_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2006.05.003","article-title":"Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis","volume":"118","author":"Dahl","year":"2006","journal-title":"J Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818300928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818300928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:15:16Z","timestamp":1761974116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818300928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S2213219818300928"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.01.037","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}